NCT01986270

Comparative Study of Oral Eletriptan (40mg and 80mg), Oral Sumatriptan (25mg and 50mg) and Placebo

A Multicenter, Double-blind, Placebo Controlled, Parallel Group, Study of Two Dose Levels of Oral Eletriptan and Two Dose Levels of of Oral Sumatriptan Given for the Acute Treatment of Migraine

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 1,141 (actual)
• Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The objective of this study was to compare the efficacy, toleration and safety of eletriptan 40mg and 80mg, with sumatriptan 25mg and 50mg, and placebo when given orally to subjects with an acute migraine.

Conditions

• Migraine With or Without Aura

Interventions

Type	Name	Description
DRUG	Placebo	Matching Placebo
DRUG	Eletriptan 40 mg	40mg oral
DRUG	Eletriptan 80 mg	80mg oral
DRUG	Sumatriptan 25 mg	25mg oral
DRUG	Sumatriptan 50 mg	50mg oral

Timeline

• Start date: 1996-12-01
• Primary completion: 1998-01-01
• Completion: 1998-01-01
• First posted: 2013-11-18
• Last updated: 2021-01-28